China Medical System Holdings Limited (CMS) disclosed that it bought back 1.01 million ordinary shares on 8 June 2026 via on-market transactions, spending HK$10.44 million.

The shares were repurchased at prices ranging between HK$10.18 and HK$10.45, with a volume-weighted average cost of HK$10.33 per share. All repurchased shares are being kept as treasury stock; none have been cancelled to date.

Capital structure impact • Outstanding shares (excluding treasury shares) fell to approximately 2.434 billion from 2.435 billion, a 0.04% reduction. • Treasury shares increased to 5.10 million from 4.09 million. • Total issued shares remain unchanged at about 2.44 billion pending any future cancellation decisions.

Repurchase mandate status • Shareholders on 23 April 2026 authorised CMS to buy back up to 243.95 million shares. • Cumulative repurchases under this mandate now total 5.10 million shares, equivalent to 0.21% of the company’s issued share base at mandate date. • Approximately 238.86 million shares, or 9.8% of the original mandate, remain available for further buybacks.

Regulatory considerations The company confirmed that the transactions complied with Hong Kong Stock Exchange listing rules. Following the repurchase, CMS is subject to a moratorium prohibiting new share issues or sales of treasury shares until 8 July 2026.